- Home
- NMTC vs BCAB Comparison
NMTC vs BCAB Comparison
Compare NMTC & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMTC
- BCAB
- Stock Information
- Founded
- NMTC 2009
- BCAB 2007
- Country
- NMTC United States
- BCAB United States
- Employees
- NMTC N/A
- BCAB N/A
- Industry
- NMTC Medical/Dental Instruments
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- NMTC Health Care
- BCAB Health Care
- Exchange
- NMTC Nasdaq
- BCAB Nasdaq
- Market Cap
- NMTC 30.9M
- BCAB 27.0M
- IPO Year
- NMTC N/A
- BCAB 2020
- Fundamental
- Price
- NMTC $0.66
- BCAB $0.41
- Analyst Decision
- NMTC Strong Buy
- BCAB Buy
- Analyst Count
- NMTC 1
- BCAB 2
- Target Price
- NMTC $1.45
- BCAB $1.00
- AVG Volume (30 Days)
- NMTC 390.9K
- BCAB 575.6K
- Earning Date
- NMTC 05-13-2025
- BCAB 05-06-2025
- Dividend Yield
- NMTC N/A
- BCAB N/A
- EPS Growth
- NMTC N/A
- BCAB N/A
- EPS
- NMTC N/A
- BCAB N/A
- Revenue
- NMTC $5,758,777.00
- BCAB $11,000,000.00
- Revenue This Year
- NMTC $292.88
- BCAB N/A
- Revenue Next Year
- NMTC N/A
- BCAB N/A
- P/E Ratio
- NMTC N/A
- BCAB N/A
- Revenue Growth
- NMTC 54.53
- BCAB N/A
- 52 Week Low
- NMTC $0.40
- BCAB $0.24
- 52 Week High
- NMTC $1.39
- BCAB $3.53
- Technical
- Relative Strength Index (RSI)
- NMTC 51.39
- BCAB 48.12
- Support Level
- NMTC $0.61
- BCAB $0.40
- Resistance Level
- NMTC $0.71
- BCAB $0.49
- Average True Range (ATR)
- NMTC 0.05
- BCAB 0.06
- MACD
- NMTC 0.02
- BCAB -0.01
- Stochastic Oscillator
- NMTC 44.03
- BCAB 5.43
About NMTC NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.